This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Makridakis, N. Articles by Reichardt, J. K. V. Search for Related Content PubMed PubMed Citation Articles by Makridakis, N. Articles by Reichardt, J. K. V.

A Prevalent Missense Substitution That Modulates Activity of Prostatic Steroid 5-Reductase¹

Department of Biochemistry and Molecular Biology [N.M., J.K.V.R.], Institute for Genetic Medicine [N.M., B.E.H., J.K.V.R.], Department of Preventive Medicine [R.K.R., M.C.P., M.C.Y., B.E.H.], and Department of Obstetrics and Gynecology [L. C., F.Z.S.], University of Southern California School of Medicine, USC/Norris Comprehensive Cancer Center, HMR413, 2011 Zonal Avenue, Los Angeles, CA 90033-1034; Cancer Research Center of Hawaii, University of Hawaii at Manoa, Honolulu, Hawaii 96813 [L.N.K.]; and Department of Community, Occupational and Family Medicine, National University of Singapore, Singapore 0511 [C-Y. S.]

Prostate cancer is the most common serious cancer diagnosed in men in the United States. This disease is also characterized by a striking racial/ethnic variation in incidence: highest in African-Americans, intermediate in Caucasians, slightly lower in Latinos, and lowest in Asians. Ample biochemical and epidemiological evidence suggests a role for androgens, particularly testosterone and dihydrotestosterone, in prostate cancer etiology. We have analyzed a candidate gene for prostate cancer, tSRD5A2, encoding prostatic steroid 5-reductase type II, which converts testosterone into the more bioactive dihydrotestosterone, for mutations. We report here one amino acid substitution, V89L, which replaces valine at codon 89 with leucine. This substitution is a "germline" (constitutional) DNA polymorphism, and it is common, panethnic, and reduces in vivo steroid 5-reductase activity. This substitution is particularly common among Asians and may explain the low risk for prostate cancer in this population.

¹ This work was supported by Grants CD 53890 (to M. C. Y.) and CA 68581 (to J. K. V. R.).

² To whom requests for reprints should be addressed, at USC-School of Medicine, Institute for Genetic Medicine, 2011 Zonal Avenue, HMR 413, Los Angeles, CA 90033. Phone: (213) 342-1529; Fax: (213) 342-2764; E-mail: reichard@zygote.hsc.usc.edu.

Received 12/ 2/96. Accepted 1/27/97.

This article has been cited by other articles:

				J. Beesley, S. J. Jordan, A. B. Spurdle, H. Song, S. J. Ramus, S. K. Kjaer, E. Hogdall, R. A. DiCioccio, V. McGuire, A. S. Whittemore, et al. Association Between Single-Nucleotide Polymorphisms in Hormone Metabolism and DNA Repair Genes and Epithelial Ovarian Cancer: Results from Two Australian Studies and an Additional Validation Set Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2557 - 2565. [Abstract] [Full Text] [PDF]

				S Leskela, E Honrado, C Montero-Conde, I Landa, A Cascon, R Leton, P Talavera, J M Cozar, A Concha, M Robledo, et al. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer Endocr. Relat. Cancer, September 1, 2007; 14(3): 645 - 654. [Abstract] [Full Text] [PDF]

				Q. Ji, L. Chang, F. Z. Stanczyk, M. Ookhtens, A. Sherrod, and A. Stolz Impaired Dihydrotestosterone Catabolism in Human Prostate Cancer: Critical Role of AKR1C2 as a Pre-Receptor Regulator of Androgen Receptor Signaling Cancer Res., February 1, 2007; 67(3): 1361 - 1369. [Abstract] [Full Text] [PDF]

				S. I. Berndt, N. Chatterjee, W.-Y. Huang, S. J. Chanock, R. Welch, E. D. Crawford, and R. B. Hayes Variant in Sex Hormone-Binding Globulin Gene and the Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 165 - 168. [Abstract] [Full Text] [PDF]

				K. J. Pienta and D. Bradley Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671. [Full Text] [PDF]

				N. Mononen, E. H. Seppala, P. Duggal, V. Autio, T. Ikonen, P. Ellonen, J. Saharinen, J. Saarela, M. Vihinen, T. L.J. Tammela, et al. Profiling Genetic Variation along the Androgen Biosynthesis and Metabolism Pathways Implicates Several Single Nucleotide Polymorphisms and Their Combinations as Prostate Cancer Risk Factors Cancer Res., January 15, 2006; 66(2): 743 - 747. [Abstract] [Full Text] [PDF]

				H. T. T. Thai, M. Kalbasi, K. Lagerstedt, L. Frisen, I. Kockum, and A. Nordenskjold The Valine Allele of the V89L Polymorphism in the 5-{alpha}-Reductase Gene Confers a Reduced Risk for Hypospadias J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6695 - 6698. [Abstract] [Full Text] [PDF]

				R. K. Nam, W. W. Zhang, M. A.S. Jewett, J. Trachtenberg, L. H. Klotz, M. Emami, L. Sugar, J. Sweet, A. Toi, and S. A. Narod The Use of Genetic Markers to Determine Risk for Prostate Cancer at Prostate Biopsy Clin. Cancer Res., December 1, 2005; 11(23): 8391 - 8397. [Abstract] [Full Text] [PDF]

				L. J. Schmidt, H. Murillo, and D. J. Tindall Gene Expression in Prostate Cancer Cells Treated With the Dual 5 Alpha-Reductase Inhibitor Dutasteride J Androl, November 1, 2004; 25(6): 944 - 953. [Abstract] [Full Text] [PDF]

				R. Foley, D. Hollywood, and M. Lawler Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488. [Abstract] [Full Text] [PDF]

				R. K. Nam, W. W. Zhang, J. Trachtenberg, M. A. S. Jewett, M. Emami, D. Vesprini, W. Chu, M. Ho, J. Sweet, A. Evans, et al. Comprehensive Assessment of Candidate Genes and Serological Markers for the Detection of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1429 - 1437. [Abstract] [Full Text] [PDF]

				C. H. van Gils, N. C. Onland-Moret, M. Roest, P. A. H. van Noord, and P. H. M. Peeters The V89L Polymorphism in the 5-{alpha}-Reductase Type 2 Gene and Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1194 - 1199. [Abstract] [Full Text]

				W. G. Nelson, A. M. De Marzo, and W. B. Isaacs Prostate Cancer N. Engl. J. Med., July 24, 2003; 349(4): 366 - 381. [Full Text] [PDF]

				C. Ntais, A. Polycarpou, and J. P. A. Ioannidis SRD5A2 Gene Polymorphisms and the Risk of Prostate Cancer: A Meta-Analysis Cancer Epidemiol. Biomarkers Prev., July 1, 2003; 12(7): 618 - 624. [Abstract] [Full Text] [PDF]

				G. Sasaki, T. Ogata, T. Ishii, K. Kosaki, S. Sato, K. Homma, T. Takahashi, T. Hasegawa, and N. Matsuo Micropenis and the 5{alpha}-Reductase-2 (SRD5A2) Gene: Mutation and V89L Polymorphism Analysis in 81 Japanese Patients J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3431 - 3436. [Abstract] [Full Text] [PDF]

				F. K. Habib, M. Ross, C. W. Bayne, P. Bollina, K. Grigor, and K. Chapman The Loss of 5{alpha}-Reductase Type I and Type II mRNA Expression in Metastatic Prostate Cancer to Bone and Lymph Node Metastasis Clin. Cancer Res., May 1, 2003; 9(5): 1815 - 1819. [Abstract] [Full Text] [PDF]

				D. J. Lamb, E. Puxeddu, N. Malik, D. L. Stenoien, R. Nigam, G. Y. Saleh, M. Mancini, N. L. Weigel, and M. Marcelli Molecular Analysis of the Androgen Receptor in Ten Prostate Cancer Specimens Obtained Before and After Androgen Ablation J Androl, March 1, 2003; 24(2): 215 - 225. [Abstract] [Full Text] [PDF]

				T. R. Rebbeck Inherited Genotype and Prostate Cancer Outcomes Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 945 - 952. [Abstract] [Full Text] [PDF]

				G. G. Giles, G. Severi, R. Sinclair, D. R. English, M. R. E. McCredie, W. Johnson, P. Boyle, and J. L. Hopper Androgenetic Alopecia and Prostate Cancer: Findings from an Australian Case-Control Study Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 549 - 553. [Abstract] [Full Text] [PDF]

				J. Simard, M. Dumont, P. Soucy, and F. Labrie Perspective: Prostate Cancer Susceptibility Genes Endocrinology, June 1, 2002; 143(6): 2029 - 2040. [Full Text] [PDF]

				C. L. Pearce, N. M. Makridakis, R. K. Ross, M. C. Pike, L. N. Kolonel, B. E. Henderson, and J. K. V. Reichardt Steroid 5-{alpha} Reductase Type II V89L Substitution Is Not Associated with Risk of Prostate Cancer in a Multiethnic Population Study Cancer Epidemiol. Biomarkers Prev., April 1, 2002; 11(4): 417 - 418. [Full Text] [PDF]

				M.-W. Yu, Y.-C. Yang, S.-Y. Yang, S.-W. Cheng, Y.-F. Liaw, S.-M. Lin, and C.-J. Chen Hormonal Markers and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: a Nested Case-Control Study Among Men J Natl Cancer Inst, November 7, 2001; 93(21): 1644 - 1651. [Abstract] [Full Text] [PDF]

				A. W. Hsing, C. Chen, A. P. Chokkalingam, Y.-T. Gao, D. A. Dightman, H. T. Nguyen, J. Deng, J. Cheng, I. A. Sesterhenn, F. K. Mostofi, et al. Polymorphic Markers in the SRD5A2 Gene and Prostate Cancer Risk: A Population-based Case-control Study Cancer Epidemiol. Biomarkers Prev., October 1, 2001; 10(10): 1077 - 1082. [Abstract] [Full Text] [PDF]

				C. A. Haiman, M. J. Stampfer, E. Giovannucci, J. Ma, N. E. Decalo, P. W. Kantoff, and D. J. Hunter The Relationship between a Polymorphism in CYP17 with Plasma Hormone Levels and Prostate Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2001; 10(7): 743 - 748. [Abstract] [Full Text] [PDF]

				A. H. Wu, A. S. Whittemore, L. N. Kolonel, F. Z. Stanczyk, E. M. John, R. P. Gallagher, and D. W. West Lifestyle Determinants of 5{{alpha}}-Reductase Metabolites in Older African-American, White, and Asian-American Men Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 533 - 538. [Abstract] [Full Text]

				N. E. Allen, M. S. Forrest, and T. J. Key The Association between Polymorphisms in the CYP17 and 5{{alpha}}-Reductase (SRD5A2) Genes and Serum Androgen Concentrations in Men Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 185 - 189. [Abstract] [Full Text]

				M. C. Bosland Chapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 39 - 66. [Abstract] [Full Text] [PDF]

				B. Bharaj, A. Scorilas, M. Giai, and E. P. Diamandis TA Repeat Polymorphism of the 5{{alpha}}-Reductase Gene and Breast Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2000; 9(4): 387 - 393. [Abstract] [Full Text]

				B. E. Henderson and H. S. Feigelson Hormonal carcinogenesis Carcinogenesis, March 1, 2000; 21(3): 427 - 433. [Abstract] [Full Text] [PDF]

				J. M. Jaffe, S. B. Malkowicz, A. H. Walker, S. MacBride, R. Peschel, J. Tomaszewski, K. Van Arsdalen, A. J. Wein, and T. R. Rebbeck Association of SRD5A2 Genotype and Pathological Characteristics of Prostate Tumors Cancer Res., March 1, 2000; 60(6): 1626 - 1630. [Abstract] [Full Text]

				P. G. Febbo, P. W. Kantoff, E. A. Platz, D. Casey, S. Batter, E. Giovannucci, C. H. Hennekens, and M. J. Stampfer The V89L Polymorphism in the 5{{alpha}}-Reductase Type 2 Gene and Risk of Prostate Cancer Cancer Res., December 1, 1999; 59(23): 5878 - 581. [Abstract] [Full Text] [PDF]

				M. Marcelli and G. R. Cunningham Hormonal Signaling in Prostatic Hyperplasia and Neoplasia J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3463 - 3468. [Full Text] [PDF]

				R. M. Lunn, D. A. Bell, J. L. Mohler, and J. A. Taylor Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2) Carcinogenesis, September 1, 1999; 20(9): 1727 - 1731. [Abstract] [Full Text] [PDF]

				L. N. Kolonel, A. M. Y. Nomura, and R. V. Cooney Dietary Fat and Prostate Cancer: Current Status J Natl Cancer Inst, March 3, 1999; 91(5): 414 - 428. [Abstract] [Full Text] [PDF]

				E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text]

				C. Lopez-Otin and E. P. Diamandis Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features Endocr. Rev., August 1, 1998; 19(4): 365 - 396. [Abstract] [Full Text] [PDF]